Sanofi, Regeneron's Dupixent aces late-stage study in young children with atopic dermatitis | Fierce Pharma
View Image
Example of case before and after treatment with dupilumab 300mg every... | Download Scientific Diagram
Example of case before and after treatment with dupilumab 300mg every... | Download Scientific Diagram
Figure 1 from Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. | Semantic Scholar
Primary (A) and secondary (B) end points in phase III trials of... | Download Scientific Diagram
Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial - Journal of the American Academy of Dermatology
Drug evaluation review: dupilumab in atopic dermatitis. | Semantic Scholar
Dupixent (dupilumab) for the Treatment of Atopic Dermatitis
JCM | Free Full-Text | Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis | HTML
A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis,Allergy - X-MOL
Modify treatment for atopic dermatitis when patient response to dupilumab is partial or non-durable | SpringerLink
Research Developments in Atopic Dermatitis • A podcast on Anchor
Dupixent | Eczema | Skin Centre | Skin Clinic |LM SKINCENTRE
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis | NEJM
Efficacy of House Dust Mite Sublingual Immunotherapy in Patients with Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Trial - The Journal of Allergy and Clinical Immunology: In Practice
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease | Nature Reviews Drug Discovery
Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2) - Journal
Profile of dupilumab and its potential in the treatment of inadequatel | CCID
dupilumab for Dermatitis Clinical Trial | Power
Clinical efficacy of Phase III trials of dupilumab for adult with... | Download Scientific Diagram
